Clinical trial
Intravesical Chemotherapy Treatment of Superficial Bladder Cancer
NCT00491114 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00491114 |
|---|---|
| Title | Intravesical Chemotherapy Treatment of Superficial Bladder Cancer |
| Official title | Intravesical Gemcitabine Therapy in Intermediate Risk Superficial Bladder Cancer: A Phase II Study With the Marker Lesion |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Neoplasms |
| Intervention type | Drug |
| Interventions | Gemcitabine |
| Enrollment | 8 |
| Start date | Jul 1, 2003 |
| Completion | Aug 1, 2004 |
| First posted | Jun 25, 2007 |
| Last update posted | Jun 25, 2007 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: